WILMETTE, Ill., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar” or the "Company”) (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative ...

GlobalData is the parent company of Clinical Trials Arena. Amgen and AstraZeneca are also investigating Tezspire in other ...

Having got off to a strong start to the year the UK economy is expected to slow in the second half of this year. In Q1 we saw the economy achieve growth of 0.6%, before slowing modestly to 0.5% in Q2, ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Tickets are available – and registration will be open right up until the day of the event – for the 2024 Protein Science in ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

Stay in the know with a recap of our top stories today. 1. AstraZeneca to open new $2b facility in Tuas by 2029, promises 800 ...

AstraZeneca is holding crisis talks with the Chinese authorities after the arrest of its boss in the country. The ...

Amgen and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial ...

AstraZeneca is building a US$1.5 billion manufacturing facility in Tuas South, Singapore, which will create over 800 jobs.

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you ...